There are several reasons your doctor might recommend you avoid GLP-1s
Answer : The major players in the GLP-1 analogues market include Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim, Pfizer, Amgen, Roche, Zealand Pharma, Structure Therapeutics, Viking Therapeutics, Hangzhou Sciwind Biosciences, Fudan University, Eccogene, Medtronic, Merck & Co., AbbVie, Bayer AG, Teva Pharmaceutical Industries Ltd., and Boehringer Ingelheim
Needle length is typically short and fine-gauge, but the exact specification varies by device
Combine with structured lifestyle intervention nutrition and physical activity amplify outcomes
For gaps of two weeks or more, many providers recommend restarting from the initial dose and titrating up again
Key points Glucagon-like peptide 1 (GLP1) receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor are widely expressed in multiple organs beyond the pancreas